The term cytokine was introduced in the early 1 970s by Cohen et al to extend the lymphokine concept.' Dumonde and coworkers in the late 1960s had introduced the term lymphokine to denote physiologically active substances (factors) produced by lymphocytes in response to antigenic stimulus (excluding antibodies).2 Cytokines are cell-active factors produced by a range of cell types in response to a range of stimuli (not only antigens) and indeed may be constitutively produced. Their essential attribute is that they interact with cells and alter their behaviour in some way. Evidently, with such a definition, cytokines include all the polypeptide hormones such as insulin, and growth factors such as epidermal growth factor. However, the classic endocrine hormones are by convention excluded. The discovery of IFNs grew out of the study of the phenomenon of viral interference-that replication of one virus may prevent the replication of another in the same cells. This phenomenon had been reported as early as 1804 by Jenner who had observed that vaccination was not successful in individuals suffering "herpetic affections". However, the key experiment was that of Isaacs and Lindenmann published in 19574: they found that the supernatant of cells treated with heat killed virus was able to prevent infection by live virus of other cells. They showed that the factor was probably protein, probably not viral in origin, not an antibody, and that its effects were not virus specific. Furthermore, the factor acted on target cells (not the virus) and some time was required to render the cells resistant to infection-to induce the "antiviral state". The factor was named "the interferon". That IFN had clinical potential that might be immense was recognised almost immediately. Mindful of the penicillin fiasco, the British authorities set up a committee to coordinate and exploit IFN research: the Scientific Committee on Interferon. This committee included representatives from the pharmaceutical industry and so one of the sociological features we see in cytokine research, big industrial money ploughed in with the expectation of huge profits through development of wonder drugs, was present in cytokine research almost from the very beginning.
1960s had introduced the term lymphokine to denote physiologically active substances (factors) produced by lymphocytes in response to antigenic stimulus (excluding antibodies).2 Cytokines are cell-active factors produced by a range of cell types in response to a range of stimuli (not only antigens) and indeed may be constitutively produced. Their essential attribute is that they interact with cells and alter their behaviour in some way. Evidently, with such a definition, cytokines include all the polypeptide hormones such as insulin, and growth factors such as epidermal growth factor. However, the classic endocrine hormones are by convention excluded. To exclude mediators such as arachidonic acid derivatives only proteins are defined as cytokines. The term interleukin was introduced in 1979 to denote polypeptide factors produced by leucocytes and active on leucocytes.' The numerical interleukin nomenclature was considered superior to trivial names dependent on the bioassay used to detect the factor, and a factor is only admitted as an interleukin when a full biochemical characterisation (gene cloning) is available. Many interleukins, which are a subset of the cytokines, are produced by cells other than leucocytes and are certainly active on non-leucocytes, therefore, the term is a misnomer, and many factors that if discovered now would be regarded as interleukins retain their older names, such as the interferons (IFN).
The IFNs were the first cytokines to be discovered and characterised. The origins of IFN research in a very real sense are the origins of cytokine research, and in this 40th anniversary year of the discovery of IFNs it seems appropriate to review how the field of IFN research has developed. Table 1 summarises the key events of the IFN story. The biology of the IFNs is a paradigm for the biology of cytokines in general: likewise, the style and flavour of IFN research-particularly the involvement of major commercial interest, and its highly competitive, sometimes frenetic, nature-is characteristic of cytokine research as a whole.
Discovery of "the interferon" and early research into the nature of the IFNs
The discovery of IFNs grew out of the study of the phenomenon of viral interference-that replication of one virus may prevent the replication of another in the same cells. This phenomenon had been reported as early as 1804 by Jenner who had observed that vaccination was not successful in individuals suffering "herpetic affections". However, the key experiment was that of Isaacs and Lindenmann published in 19574: they found that the supernatant of cells treated with heat killed virus was able to prevent infection by live virus of other cells. They showed that the factor was probably protein, probably not viral in origin, not an antibody, and that its effects were not virus specific. Furthermore, the factor acted on target cells (not the virus) and some time was required to render the cells resistant to infection-to induce the "antiviral state". The factor was named "the interferon". That IFN had clinical potential that might be immense was recognised almost immediately. Mindful of the penicillin fiasco, the British authorities set up a committee to coordinate and exploit IFN research: the Scientific Committee on Interferon. This committee included representatives from the pharmaceutical industry and so one of the sociological features we see in cytokine research, big industrial money ploughed in with the expectation of huge profits through development of wonder drugs, was present in cytokine research almost from the very beginning.
It was quickly found that IFN could be produced by a range of cell types in response to many viruses and some non-viral It seems reasonable to attribute the increased sensitivity to viruses of IFNct knockout mice to the failure of the direct antiviral mechanism in these animals. The sensitivity of IFNy knockout mice to bacterial and parasitic infections is best interpreted as resulting from the failure of activation by IFNy of macrophages and granulocytes for the "oxidative burst", the production of oxygen radicals and nitric oxide. Clearly, IFNy is involved in classic inflammatory mechanisms: inappropriate or uncontrolled production of IFNy (together with other pro-inflammatory cytokines) is widely accepted as one of the principal mechanisms of tissue injury, and may be of key importance in the development of autoimmune diseases of many sorts.
Interaction of IFNs with cells: receptors and signal transduction
Perhaps the most exciting area of cytokine research today is the elucidation of the intracellular pathways by which they exert their effects. Again, the IFNs provide an excellent model for other cytokines. By definition, cytokines act on cells. As they are proteins, they are unable to diffuse into the cell (unlike for example, steroid hormones) and so must achieve their effects through interaction with cell surface receptors. By the early 1 980s it was shown that IFNa and f shared a common receptor but that IFNy had a different receptor (beginning to provide an explanation for their differing biological activities). From the early days of IFN 29) to turn on a second wave of gene induction.
Molecular genetic techniques have clarified the nature of the interaction of IFNs with their receptors and how this changes the cell's behaviour (fig 1) . The cloning of the receptor for IFNa and 13 was initially uninformative. It was unrelated to growth factor receptors and G-protein linked receptors and had no obvious enzyme activity (such as tyrosine kinase). When transfected into heterologous cells (IFNs are to a large extent species specific, therefore, mouse IFN will not bind to or act on human cells), although these now bound IFN, no signal for induction of the antiviral effect was transmitted. 30 The explanation is simple, the ligand binding component of the receptor had been cloned, but this requires specific interaction with other components for efficient signal transduction. The IFN receptors are in fact prototypes for a new family of multicomponent cytokine receptors, which function in a manner distinct from the other major receptors, growth factor and G-protein linked receptors.
The IFNy receptor has been studied in considerable detail. The finding that IFNs have growth inhibitory properties led to trials of its efficacy in cancer. As with the antiviral effect, the anticancer effect proved largely illusory. Only with a few, usually very rare cancers, has IFN treatment been effective. One example is hairy cell leukaemia, of which there are perhaps one or two cases a year in a large haematology unit.
IFNs have found some clinical efficacy in a one or two other diseases. The activation by IFN'y of antimicrobial mechanisms in macrophages (and other leucocytes) is probably the basis for the efficacy of IFNy in chronic granulomatous disease, a rare disease with an inherited defect in the oxidative enzymes of myeloid cells.4" Likewise, IFN,B has some effect in multiple sclerosis, it reduces the relapse rate but as yet it is not clear whether there is long term benefit. 44 The high cost of the treatment (about £33 000 per relapse avoided) puts into doubt whether it will be used widely. 45 Despite this rather negative clinical picture, IFN as a drug is much used, perhaps predominately against hepatitis C (it is rumoured that one eighth of the Japanese pharmaceutical market is IFNa) with annual world sales in the billion dollar region.
What next? There have been several occasions when it has appeared that IFN research was over. This has usually been just before some new flurry of important experimental results of general interest to all involved in cytokine research.
There are still many gaps.46 One cannot predict the future, but one feels it to be relatively rosy from an IFN researcher's point of view: papers published annually with IFN in the title are increasing: 1773, 1896, 2108, 2203, and 2646 hits from the Science Citation Index for the years 1992-96, respectively. There is continued interest in the biology of IFNs, which has been germinal for cytokine research since the beginning, with by now a longer history than many of those studying it.
